Christopher A. Haiman
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
ACS IMPACT Research Professorship in Prostate Cancer
Open Date: 2024-07-01
Close Date: 2029-06-30
Articles (28)
Supplementary Table S5 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease in the Pancreatic Cancer Case-Control Consortium (PanC4) data
Year:
2025
Supplementary Table S1 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease SNPs in the Pancreatic Cancer Cohort Consortium (PanScan) data
Year:
2025
Frequencies of all reported germline CHEK2 variant carriers and carriers of variants concordantly categorized by functional our kinase assays in breast cancer patients and controls in 12 analyzed population datasets.
Year:
2025
Supplemental Table 3 shows the associations between adherence to the WCRF/AICR health behavior recommendations and risk of mortality after excluding participants who died within 6, or 12, or 24 months of diagnosis; or those with distant disease at diagnosis; or those with missing data.
Year:
2025
Supplemental Table 1 shows comparisons of characteristics between eligible participants (all those diagnosed with colorectal cancer between enrollment and Q3) and those included in the final study sample.
Year:
2025
Supplemental Figure S2. Meta-analysis full forest plots from AABCG for rs2814778 in relation to risk of breast cancer overall, ER- and TNBC. Figure shows non-significant odds ratio (OR) estimates for breast cancer risk overall, ER- and TNBC for ACKR1/DARC variant, rs2814778 in reference to controls.
Year:
2025
Background: Immune response in blood varies by ancestry, linked to an African-specific variant (rs2814778) in the Duffy Antigen Receptor for Chemokines ( DARC / ACKR1 ) gene. We examined associations between rs2814778, CD8 + T-cell density in breast tumors, and breast cancer risk in African-American/Black women. Methods: CD8 + T-cell density in tumors from 428 Black women were examined in relation to the rs2814778 variant. In the African Ancestry Breast Cancer Genetics (AABCG) Consortium with 16,886 cases and 18,044 controls, rs2814778 was evaluated in relation to risk of overall breast cancer and to more aggressive subtypes [estrogen receptor-negative (ER−) and triple-negative breast cancer (TNBC)]. Results: Women with the African-specific CC genotype had lower tumor CD8 + T-cell density (87.0 per mm 2 ) than those with TT genotypes (146.6 per mm 2 ; P T allele was significantly associated with an increase in T-cell density ( P = 0.04). In the largest analysis, to date, there were no associations between rs2814778 and risk of overall breast cancer [OR = 0.90 (95% confidence interval (CI), 0.66–1.22)] or with ER− breast cancer [OR = 0.86 (95% CI, 0.68–1.08)] or TNBC [OR = 0.77 (95% CI, 0.56–1.05)]. Conclusions: Although breast tumors from women with the African-specific DARC C allele had lower CD8 + T-cell density levels than those with T alleles, in a large breast cancer consortium with adequate statistical power, the variant was not associated with breast cancer risk overall, nor with risk of ER− breast cancer or TNBC, as previously hypothesized. Impact: Although the “Duffy-null” allele has been the focus of research as a contributor to aggressive breast cancer in Black women, this study with 34,930 cases and controls found no associations with risk.
Year:
2025
Supplemental Figure S1. Log-transformed CD8+ T-cell density per mm2 by ACKR1/DARC genotype. Figure displays box plot distribution of CD8+ T-cell density per mm2 according to ACKR1/DARC genotype (N=428).
Year:
2025
Background: Racial and ethnic minority patients with colorectal cancer are underrepresented in studies on health behavior and mortality. Methods: We examined the association between postdiagnosis health behavior and mortality in the Multiethnic Cohort, a diverse group of 215,000 participants from Hawaii and Los Angeles (recruited 1993–1996). Follow-up was through December 31, 2019. Postdiagnosis health behavior was assessed using a modified World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) score (excluding ultraprocessed foods). The primary outcome was overall mortality, and the secondary outcome was colorectal cancer–specific mortality. Results: Among 1,079 eligible participants, 489 (45.3%) were women and 850 (78.8%) self-identified as racially/ethnically minoritized people. Over a median follow-up of 12.2 years, there were 613 all-cause deaths and 105 colorectal cancer–related deaths. The median time from diagnosis to questionnaire completion was 5 years (IQR: 2–8). Higher WCRF/AICR scores (4.5–7) were associated with lower risk of overall mortality compared with lower scores [≤2.25; HR = 0.63; 95% confidence interval (CI), 0.45–0.87]. Risk of colorectal cancer–specific mortality was also lower but not statistically significant. Among individual health behaviors, physical activity was associated with lower risk of all-cause and colorectal cancer–specific mortality (reference: Conclusions: Higher adherence to WCRF/AICR guidelines, particularly engaging in moderate-to-vigorous physical activity, was associated with lower risk of mortality in long-term colorectal cancer survivors. Impact: These findings support the generalizability of prior studies examining adherence to WCRF/AICR guidelines to a broader group of patients with colorectal cancer.
Year:
2025
Background: A substantial portion of the genetic predisposition for breast cancer is explained by multiple common genetic variants of relatively small effect. A subset of these variants, which have been identified mostly in individuals of European (EUR) and Asian ancestries, have been combined to construct a polygenic risk score (PRS) to predict breast cancer risk, but the prediction accuracy of existing PRSs in Hispanic/Latinx individuals (H/L) remain relatively low. We assessed the performance of several existing PRS panels with and without addition of H/L-specific variants among self-reported H/L women. Methods: PRS performance was evaluated using multivariable logistic regression and the area under the ROC curve. Results: Both EUR and Asian PRSs performed worse in H/L samples compared with original reports. The best EUR PRS performed better than the best Asian PRS in pooled H/L samples. EUR PRSs had decreased performance with increasing Indigenous American (IA) ancestry, while Asian PRSs had increased performance with increasing IA ancestry. The addition of two H/L SNPs increased performance for all PRSs, most notably in the samples with high IA ancestry, and did not impact the performance of PRSs in individuals with lower IA ancestry. Conclusions: A single PRS that incorporates risk variants relevant to the multiple ancestral components of individuals from Latin America, instead of a set of ancestry-specific panels, could be used in clinical practice. Impact: The results highlight the importance of population-specific discovery and suggest a straightforward approach to integrate ancestry-specific variants into PRSs for clinical application.
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (132)
Rayjean Hung
University of Toronto
Jean Yves Masson
Full Professor
Université Laval Faculté de médecine
Neal Freedman
Branch Chief
National Cancer Institute
Montserrat Garcia-Closas
Professor of Epidemiology
Institute of Cancer Research
Tomáš Zima
Head of Institute
Charles University and General University Hospital in Prague, First Faculty of Medicine
Kathleen Claes
Full professor
Ghent University Hospital
Giuseppe Matullo
-
Lisa Wiesmüller
Professor
Ulm University
Laura Fejerman
Professor
University of California, Davis
Andriy Derkach
Associate Attending Biostatistician
Memorial Sloan Kettering Cancer Center
Christine Ambrosone
Roswell Park Comprehensive Cancer Center
Jennifer Hu
Professor
University of Miami
Eric Hahnen
-
Susan Domchek
Professor, Clinician-Educator
University of Pennsylvania
Sara Lindström
University of Washington
Ian M. Thompson
University of Texas Health Science Center at San Antonio
Maria Rossing
Associate Clinical Professor
Copenhagen University Hospital
Marco Montagna
Istituto Oncologico Veneto
Katherine Nathanson
Professor
University of Pennsylvania
Jacques Simard
Full Professor
Laval University
Xiao‐Ou Shu
Vanderbilt University Medical Center
Nicoletta Resta
Full Professor Medical Genetics
University of Bari Aldo Moro
Song Yao
Professor
Roswell Park Comprehensive Cancer Center
Maria Piane
Sapienza University of Rome
Lynne Wilkens
Professor
University of Hawaii at Manoa
Sara González
Institut Català d'Oncologia
Shiv Prakash Verma
Senior Research Scientist
Memorial Sloan Kettering Cancer Center
FEI CHEN
Assistant Professor
University of Southern California
Anne Tjonneland
Professor
Københavns Universitet
June M. Chan
Professor
University of California
Katie O'Brien
Staff Scientist
National Institute of Environmental Health Sciences
A Heather Eliassen
Professor
Harvard University
Irene Ong
Associate Professor
University of Wisconsin-Madison
Ulrike Peters
Fred Hutchinson Cancer Research Center
Song-Yi Park
-
Alexandra Martins
INSERM
Stefan Ambs
Senior Investigator (tenured) and Head of the Molecular Epidemiology Section
National Cancer Institute
Dale Sandler
Branch Chief
National Institute of Environmental Health Sciences
Julie R Palmer
Boston University School of Medicine
Clarice Weinberg
Principal Investigator
National Institute of Environmental Health Sciences
Alexander E Volk
-
Weang Kee Ho
Professor
Sunway University
gaofeng cui
Assistant professor
Mayo Clinic
Wei Zheng
-
Miquel Porta
-
Peter Kraft
Professor
Harvard T.H. Chan School of Public Health
Kari Rabe
Assistant Professor of Biostatistics
Mayo Clinic
Yara G Abdou
University of North Carolina at Chapel Hill
Bizu Gelaye
Chief, Epidemiology Branch and Senior Investigator
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Siddhartha Yadav
Associate Professor of Oncology
Mayo Clinic
Mariarosaria Calvello
European Institute of Oncology
Stephen Chanock
National Institutes of Health
Alison Klein
Professor
-
Qiuyin Cai
Professor
Vanderbilt University Medical Center
anna coppa
Sapienza University of Rome
Allison DePersia
NorthShore University HealthSystem
Stacey Kenfield
University of California, San Francisco
Paul James
Head of Adult Genetics
The Royal Melbourne Hospital Royal Park Campus
Florentia Fostira
National Centre for Scientific Research-Demokritos
Paolo Radice
Head of Reserach Unit
Fondazione IRCCS Istituto Nazionale dei Tumori
Maria Elena. Martinez
University of California
Federico Canzian
Group Leader
Deutsches Krebsforschungszentrum
Marketa Janatova
Assistanf Professor and researcher
Přírodovědecká Fakulta, Univerzita Karlova
Herbert Yu
Researcher/Professor
University of Hawaii at Manoa
Melissa A. Troester
Professor
University of North Carolina at Chapel Hill
Iona Cheng
University of California
Yuan-Ping Pang
Professor of Biophysics and Pharmacology
Mayo Clinic
Eva S. Schernhammer
Medical University of Vienna
Elad Ziv
Professor
University of California
GUOCHONG JIA
Vanderbilt University
Martijn C.G.J. Brouwers
-
Andrew Olshan
University of North Carolina at Chapel Hill
Gareth Evans
The University of Manchester
Esther John
Professor
Stanford University School of Medicine
Charles F. Lynch
-
Chi-Chen Hong
Associate Professor of Oncology
Roswell Park Comprehensive Cancer Center
Weng Khong Lim
Assistant Professor
Duke-NUS Medical School
Barbara Pasini
Associate Professor of Medical Genetics
Università degli Studi di Torino
Dezheng Huo
University of Chicago
Ian Campbell
Group Leader
Peter MacCallum Cancer Institute
Gordon Watt
Junior Group Leader
The Netherlands Cancer Institute
Stacey J. Winham
Mayo Clinic College of Medicine and Science
Unnur Valdimarsdottir
Professor
Karolinska Institutet
Xingyi Guo
Associate Professor
Vanderbilt University Medical Center
Jeffrey Weitzel
Professor and Director
University of Kansas Cancer Center
Thilo Hackert
University Hospital Heidelberg
Elio Riboli
Professor of Cancer Epidemiology
Imperial College London
Rachael Solomon
Senior Eoidemiologist
Division of Cancer Epidemiology and Genetics, National Cancer Institute
Luis G Carvajal‐Carmona
Professor
University of California, Davis
Jean Wactawki-Wende
Dean, Suny Distinguished Professor
University at Buffalo
Jirong Long
Professor
Vanderbilt University Medical Center
Malin Sund
Professor/Consultant
University of Helsinki
Banu K. Arun
The University of Texas MD Anderson Cancer Center
Paul Auer
Professor
Medical College of Wisconsin
Loic Le Marchand
Professor
University of Hawaii
Donghui Li
Professor
The University of Texas MD Anderson Cancer Center
Jo Freudenheim
SUNY Distinguished Professor and Associate Dean
University at Buffalo
Hoda Anton-Culver
Professor and Chair
University of California, Irvine
David Conti
Professor
Colorado School of Public Health
Anne Zeleniuch-Jacquotte
Professor of Population Health and Environmental Medicine
NYU School of Medicine
Maegan Roberts
Assistant Professor
Ohio State University
Alan Arslan
Associate Professor
NYU Langone Medical Center
Alvaro Monteiro
Senior Member - Full Professor
H Lee Moffitt Cancer Center and Research Institute
Michelle Williams
Professor of Epidemiology
Stanford University
Yaohua Yang
Assistant Professor
University of Virginia
Corinna Ernst
Hannover Medical School
Nuria Malats
Group Leader
Centro Nacional de Investigaciones Oncológicas
Sarah C. Markt
Case Western Reserve University
Kala Visvanathan
Professor
Johns Hopkins University
Steven Hart
Mayo Clinic
Manal M. Hassan
Professor
The University of Texas MD Anderson Cancer Center
Allison W Kurian
Professor
Stanford University School of Medicine
Veronica Setiawan
Associate Professor
University of Southern California
Jian Gu
The University of Texas MD Anderson Cancer Center
Charles Kooperberg
Fred Hutchinson Cancer Research Center
Kathryn Ruddy
Professor
Mayo Clinic
Olufunmilayo I. Olopade
Professor
University of Chicago
Lidia Feliubadaló
Institut Català d'Oncologia
Christopher Li
Fred Hutchinson Cancer Research Center
Koichi Matsuda
University of Tokyo
Kimberly A. Bertrand
Associate Professor of Medicine
Boston University
Bingshan Li
Vanderbilt University
Joanne Ngeow
Head
Nanyang Technological University (NTU)
Eric Polley
Associate Professor
University of Chicago
Elisa Bandera
Chief
Rutgers Cancer Institute of New Jersey
Zdenek Kleibl
Laboratory of oncogenetics (head)
Charles University, First Faculty of Medicine
Graham Giles
Head of Research
-
Nicholas Boddicker
Research Associate
Mayo Clinic
Amanda Toland
Ohio State University
Argyrios Ziogas
Professor
University of California, Irvine
Laura Cortesi
University of Modena and Reggio Emilia
Manolis Kogevinas
Senior Researcher
Barcelona Institute for Global Health
Make your next move.
Prepare your application
Review drafts before you send them.